Neurorestorative efficacy of PYM50028 (Cogane™) in rodent and primate models of Parkinson's disease: Translation to dosing in humans

被引：0
|
作者：
Johnston, T. H.
Fox, S. H.
Koprich, J. B.
Huot, P.
Ward, C. L.
Meyers, N.
Howson, P. A.
Brotchie, J. M.
机构：
来源：
MOVEMENT DISORDERS | 2010年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S415 / S415
页数：1
相关论文
共 24 条
  • [21] Potential applications of the α2-adrenergic antagonist, JP-1730, in reducing the problem of L-dopa-induced motor fluctuations in Parkinson's disease:: Studies in the rodent and primate models of Parkinson's disease
    Hill, MP
    Savola, JM
    Merivuori, H
    McGuire, SG
    Crossman, AR
    Brotchie, JM
    MOVEMENT DISORDERS, 2002, 17 : S71 - S71
  • [22] Mu-opioid receptor number is decreased in the output regions of the basal ganglia in primate and rodent models of L-DOPA-induced dyskinesia in Parkinson's disease
    Begum, S
    Crossman, AR
    Brotchie, J
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 : 114 - 114
  • [23] A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease
    Schneider, Jay S.
    Marshall, Courtney A.
    Keibel, Lauren
    Snyder, Nathaniel W.
    Hill, Michael P.
    Brotchie, Jonathan M.
    Johnston, Tom H.
    Waterhouse, Barry D.
    Kortagere, Sandhya
    EXPERIMENTAL NEUROLOGY, 2021, 335
  • [24] The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with L-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease
    Jones, Carrie K.
    Bubser, Michael
    Thompson, Analisa D.
    Dickerson, Jonathan W.
    Turle-Lorenzo, Nathalie
    Amalric, Marianne
    Blobaum, Anna L.
    Bridges, Thomas M.
    Morrison, Ryan D.
    Jadhav, Satyawan
    Engers, Darren W.
    Italiano, Kimberly
    Bode, Jacob
    Daniels, J. Scott
    Lindsley, Craig W.
    Hopkins, Corey R.
    Conn, P. Jeffrey
    Niswender, Colleen M.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 340 (02): : 404 - 421
123